LifeNet Health’s Dermacell AWM® offers unsurpassed effectiveness at unparalleled value for DFU treatment
LifeNet Health’s Dermacell AWM® offers unsurpassed effectiveness at unparalleled value for DFU treatment
Analysis presented at SAWC shows up to 94 percent cost reduction for treating complex DFUs — with an average of just one application
May 8, 2019 — SAN ANTONIO, Texas — LifeNet Health’s Dermacell AWM® acellular dermal matrix reduced the cost to heal complex Diabetic Foot Ulcers (DFUs) by up to 94 percent compared to a leading viable cryopreserved human placental membrane (vCHPM), according to a cost analysis being presented at the SAWC Spring conference.